Domain of EPI suite biotransformation models.
1US Environmental Protection Agency, Office of Pollution Prevention and Toxics 7406M, Washington, DC 20460, USA. Boethling.bob@epa.gov
SAR and QSAR in Environmental Research
|September 7, 2010
Summary
Characterizing the applicability domain (AD) of biotransformation models improves predictions. Range-based AD methods showed promise for continuous variables, while structure-based methods were more effective for classification tasks.
Area of Science:
- Computational chemistry
- Environmental science
- Toxicology
Background:
- Predictive accuracy in structure-activity relationships (SARs) relies on understanding the applicability domain (AD).
- EPI Suite software is widely used for environmental fate and transport predictions.
Purpose of the Study:
- To characterize the AD of EPI Suite biotransformation models.
- To evaluate the performance of various AD assessment methods for these models.
Main Methods:
- Applied AD methods to training sets of four EPI Suite models (two continuous, two classification).
- Evaluated predictive accuracy using six independent validation sets.
- Utilized range-based approaches with principal component analysis and structure-based methods (fingerprints, atom environments).
Main Results:
- Range-based AD methods effectively identified subsets with higher prediction errors for continuous variables (BCFBAF, BioHCwin).
- Structure-based AD methods showed some success for classification models (Biowin3, Biowin5).
- Descriptor-based AD methods were ineffective for identifying misclassified chemicals; molecular weight alone was insufficient for Biowin3.
Conclusions:
- AD characterization is crucial for enhancing the reliability of biotransformation predictions.
- The choice of AD method depends on the model's endpoint (continuous vs. classification).
- Further refinement of models like Biowin3 is needed, potentially by revising fragment libraries.
Related Concept Videos
Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drug Biotransformation: Overview
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
